Evaluation of E1A double mutant oncolytic adenovectors in anti-glioma gene therapy

Ilya V. Ulasov, Matthew A. Tyler, Angel A. Rivera, Dirk M. Nettlebeck, Joanne T. Douglas, Maciej S. Lesniak

Research output: Contribution to journalArticlepeer-review

21 Scopus citations


Malignant glioma, in particular glioblastoma multiforme (GBM), represents one of the most devastating cancers currently known and existing treatment regimens do little to change patient prognosis. Conditionally replicating adenoviral vectors (CRAds) represent attractive experimental anti-cancer agents with potential for clinical application. However, early protein products of the wild type adenovirus backbone - such as E1A - limit CRAds' replicative specificity. In this study, we evaluated the oncolytic potency and specificity of CRAds in which p300/CPB and/or pRb binding capacities of E1A were ablated to reduce non-specific replicative cytolysis. In vitro cytopathic assays, quantitative PCR analysis, Western blot, and flow cytometry studies demonstrate the superior anti-glioma efficacy of a double-mutated CRAd, Ad2/24CMV, which harbors mutations that reduce E1A binding to p300/CPB and pRb. When compared to its single-mutated and wild type counterparts, Ad2/24CMV demonstrated attenuated replication and cytotoxicity in representative normal human brain while displaying enhanced replicative cytotoxicity in malignant glioma. These results have implications for the development of double-mutated CRAd vectors for enhanced GBM therapy.

Original languageEnglish (US)
Pages (from-to)1595-1603
Number of pages9
JournalJournal of Medical Virology
Issue number9
StatePublished - Sep 2008


  • Ad2/24
  • Adenovirus
  • Gene therapy
  • Glioma
  • Oncolytic virus
  • Virotherapy

ASJC Scopus subject areas

  • Infectious Diseases
  • Virology


Dive into the research topics of 'Evaluation of E1A double mutant oncolytic adenovectors in anti-glioma gene therapy'. Together they form a unique fingerprint.

Cite this